Unilabs – York Bioanalytical Solutions, YBS, appoints Dr. Viv Willson to strengthen the immunoassay team in Copenhagen

YBS today announced a new collaboration with Dr.Viv Willson who will be working within the Drug Development Services (DDS) section at Unilabs YBS in Copenhagen.

Dr. Willson’s recent experience in setting up the immunoassay facility at YBS in York and the client contacts he developed as a result will be valuable in developing and promoting new technology in the DDS section in Copenhagen and in applying this to forthcoming drug development projects.

YBS is dedicated to continuous renewal of its technical platforms and recent new innovations include; new immunoassay technology comprising the Gyrolab system for automating high throughput immunoassay methods and the Meso Scale Discovery (MSD) system for added sensitivity, selectivity and multiple biomarker analysis using electrochemiluminescence.

“Viv’s long and proven experience in immunoassay and drug development will be an asset to the immunoassay team in Copenhagen and our client partners,” said Yvonne Lech, Managing Director of Unilabs Denmark.

In addition to immunoassay expertise and over 25 years of drug development experience, Dr. Willson has special interests in Biomarker analysis and in the assessment of antigenicity of biologicals. His background in Clinical Chemistry leaves him well placed to advise on healthcare support at Unilabs YBS.

Viv was educated at Trinity College, Cambridge and then undertook postdoctoral work with Prof. Nick Hales at Addenbrookes Hospital in Cambridge on organ specific proteins. One of the most notable outcomes of this work was the development of one of the earliest specific immunoassay methods for the cardiac marker Creatine Kinase MB. Prior to the more recent adoption of Troponin, CK MB was for many years used as a key early diagnostic marker for heart attacks due to myocardial infarction.